Coversyl(R) in PEPCHF Trial, has been the first agent to demonstrate clinical benefits in elderly heart failure patients with diastolic dysfunction. The drug appears to provide a number of clinical ...
This leaflet answers some common questions about COVERSYL PLUS. It does not contain all the available information about this medicine. Reading this leaflet does not take the place of talking to your ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
October 27, 2006 — Health Canada has approved a new indication for perindopril erbumine, allowing its use to reduce the risk for cardiovascular adverse events and mortality in patients with stable ...
-- New Analysis of ASCOT-BPLA Data Identifies Major Predictors of NOD Among Hypertensives A new analysis of data from the landmark Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering ...
-- Coversyl(R) in PEP-CHF Trial, is the First Agent to Demonstrate Clinical Benefits in Elderly Heart Failure Patients With Diastolic Dysfunction The ACE inhibitor Coversyl(R) (perindopril) provides a ...
Servier was on the up yesterday after the European regulators cleared the way for its blood pressure drug Coversyl (perindopril) to be launched in a new indication – treating patients with stable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results